Michael Kaseta Sells 8,283 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 8,283 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $112,400.31. Following the completion of the sale, the chief financial officer now owns 396,315 shares in the company, valued at approximately $5,377,994.55. This trade represents a 2.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Liquidia Trading Up 0.6 %

Liquidia stock traded up $0.08 during trading hours on Wednesday, reaching $13.68. 704,101 shares of the stock were exchanged, compared to its average volume of 966,317. The stock has a 50 day moving average of $14.79 and a two-hundred day moving average of $12.72. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81. The company has a market cap of $1.17 billion, a P/E ratio of -8.39 and a beta of 0.23.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. On average, analysts expect that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Institutional Trading of Liquidia

A number of hedge funds and other institutional investors have recently modified their holdings of LQDA. LM Advisors LLC acquired a new stake in shares of Liquidia during the fourth quarter valued at about $25,948,000. Invesco Ltd. increased its position in shares of Liquidia by 2,675.0% during the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company’s stock worth $8,234,000 after buying an additional 674,940 shares during the period. Janus Henderson Group PLC grew its holdings in Liquidia by 1,484.5% during the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company’s stock worth $6,293,000 after acquiring an additional 501,752 shares during the period. Mirabella Financial Services LLP bought a new stake in Liquidia in the fourth quarter worth approximately $5,880,000. Finally, Eversept Partners LP increased its stake in shares of Liquidia by 314.1% in the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company’s stock valued at $6,719,000 after acquiring an additional 433,356 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LQDA. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC restated a “buy” rating and set a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research report on Thursday, March 20th. Finally, Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $26.63.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).